DEFA14A: Cardinal Health Updates Proxy Statement Following Director's Appointment as Interim CEO of Masimo

Cardinal Health has updated its proxy statement to reflect that director Michelle M. Brennan no longer qualifies as an independent director due to her appointment as interim CEO of Masimo Corporation, a company with which Cardinal Health has a significant commercial relationship.

Summary

• Cardinal Health has filed a supplement to its proxy statement for the 2024 Annual Meeting of Shareholders, scheduled for November 6, 2024.
• The supplement addresses the change in director Michelle M. Brennan's independence status.
• Ms. Brennan was appointed interim CEO of Masimo Corporation on September 24, 2024.
• Cardinal Health has a pre-existing commercial relationship with Masimo, purchasing products for distribution.
• From July 1, 2023, through August 31, 2024, Cardinal Health made payments of approximately $132 million to Masimo for product purchases.
• The Audit Committee has approved these transactions in accordance with the company's Related Person Transactions Policy.
• Due to her employment with Masimo and the ongoing commercial relationship, Ms. Brennan is no longer considered an independent director.
• She will remain on the Board but will no longer serve on the Audit Committee or the Human Resources and Compensation Committee.
• Robert W. Azelby was appointed to the Audit Committee, and Gregory B. Kenny was appointed to the Human Resources and Compensation Committee, effective September 29, 2024.

Sentiment

Score: 6

Explanation: The announcement is neutral, detailing a change in director status and committee assignments. While the loss of an independent director is a slight negative, the company is taking steps to address the situation.

Positives

• The Audit Committee approved the transactions with Masimo, ensuring compliance with the Related Person Transactions Policy.
• Cardinal Health is addressing the change in director independence promptly and transparently.
• The company has appointed new members to the Audit Committee and Human Resources and Compensation Committee to fill the vacancies.

Negatives

• A director, Michelle M. Brennan, is no longer considered independent due to her role as interim CEO of Masimo, a company with which Cardinal Health has a significant commercial relationship.
• Ms. Brennan's change in status requires her removal from key committees (Audit and Human Resources and Compensation).

Risks

• The commercial relationship between Cardinal Health and Masimo could raise potential conflicts of interest given Ms. Brennan's dual roles.
• The loss of an independent director from key committees could impact the committees' decision-making processes.

Industry Context

The appointment of a director to a leadership role at a significant supplier highlights the interconnectedness within the healthcare industry and the potential for conflicts of interest. Companies must carefully manage these relationships to maintain independence and transparency.

Comparison to Industry Standards

• Companies like McKesson and AmerisourceBergen, which are also major players in pharmaceutical distribution, typically have strict policies regarding director independence to avoid conflicts of interest with suppliers.
• The $132 million in payments to Masimo is a significant amount, suggesting a material relationship that warrants careful scrutiny, similar to how large contracts between pharmaceutical companies and research organizations are reviewed for potential bias.
• The appointment of new members to the Audit and Compensation committees is a standard practice to ensure continued oversight and governance, mirroring the actions taken by other publicly traded companies when faced with similar situations.

Corporate Governance

Related Party Transactions

• Cardinal Health made payments to Masimo of approximately $132 million for product purchases between July 1, 2023, and August 31, 2024.
• These transactions have been approved by the Audit Committee in accordance with the company's Related Person Transactions Policy.

Stakeholder Impact

• Shareholders should be aware of the potential conflict of interest arising from the director's role at Masimo.
• The changes in committee membership could impact the oversight and governance of the company.

Key Dates

Keywords

Cardinal Health, Masimo, Director Independence, Related Person Transaction, Proxy Statement, Audit Committee, Human Resources and Compensation Committee, Michelle M. Brennan, Robert W. Azelby, Gregory B. Kenny